Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for VNDA
0.00 (0.00%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.80 - 15.51
Open     -
Vol / Avg. 0.00/656,107.00
Mkt cap 424.73M
P/E 8.46
Div/yield     -
EPS 1.17
Shares 42.82M
Beta 1.65
Inst. own 108%
Feb 17, 2016
Q4 2015 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2015
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 2:30PM EST - Add to calendar
Nov 19, 2015
Vanda Pharmaceuticals Inc at Jefferies Autumn Global Healthcare Conference
Nov 16, 2015
Vanda Pharmaceuticals Inc at Brean Capital Life Sciences Summit Conference
Nov 5, 2015
Vanda Pharmaceuticals Inc at Citi Global Healthcare Conference
Nov 3, 2015
Q3 2015 Vanda Pharmaceuticals Inc Earnings Call - Webcast
Nov 3, 2015
Q3 2015 Vanda Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -33.38% 40.25%
Operating margin -33.66% 40.00%
EBITD margin - -109.20%
Return on average assets -17.08% 12.81%
Return on average equity -25.67% 19.70%
Employees 112 -
CDP Score - -


Suite 300E, 2200 Pennsylvania Ave NW
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Officers and directors

H. Thomas Watkins Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Richard L Gulino Senior Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Thomas Edward Gibbs Senior Vice President, Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Gian Piero Reverberi Senior Vice President, European General Manager
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 55
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 73
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters